• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无晚期肝纤维化的非酒精性脂肪性肝病患者骨密度增加:来自2017 - 2020年美国国家健康与营养检查调查数据库的证据

Increased BMD in SLD Patients Without Advanced Hepatic Fibrosis: Evidence From the NHANES 2017-2020 Database.

作者信息

Wu Tianhao, Li Lu, Mei Yayuan, Lv Peizhen, Cui Jiawei, Liu Lin, Nan Yuemin, Li Ang

机构信息

Department of Orthopedic Surgery, Hebei Medical University Third Hospital, Shijiazhuang 050051, Hebei, China.

Department of Gastroenterology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China.

出版信息

Can J Gastroenterol Hepatol. 2025 Aug 11;2025:6969761. doi: 10.1155/cjgh/6969761. eCollection 2025.

DOI:10.1155/cjgh/6969761
PMID:40831492
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12360881/
Abstract

Recently, metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed to replace the liver condition previously known as nonalcoholic fatty liver disease (NAFLD), thereby redefining the subcategories of steatotic liver disease (SLD). However, the clinical relevance of SLD subcategories and their relationship with bone mass is lacking. In this study, we aimed to explore the potential association between the commonly proposed subclasses of fatty liver disease and bone mass. A cross-sectional study using the data from the 2017-2020 cycle of the National Health and Nutrition Examination Survey (NHANES), involving 4237 participants aged 18 years and older who underwent vibration-controlled transient elastography (VCTE) and dual-energy X-ray absorptiometry (DXA), was conducted. A weighted generalized linear model was used to analyze the association of the SLD subcategories and bone mass changes including bone mineral content (BMC), bone area, and bone mineral density (BMD) in the femur and spine, with adjustments for potential covariates. Furthermore, a weighted generalized additive model was employed to assess the dose-response relationships between controlled attenuation parameter (CAP), liver stiffness measurement (LSM), and BMD. A total of 2635 and 1602 participants were included for analysis of the femur and lumbar spine, respectively. Compared to healthy individuals, positive correlations were observed between all three SLD subgroups (MASLD, MetALD, and ALD) and BMC, and BMD in the femur and spine, but no association with the bone area was identified. Moreover, CAP exhibited a strong positive correlation with BMD across all femoral and spinal scan sites. It was also positively correlated with BMC in some femoral scan sites and all spinal scan sites but was associated with the bone area only in certain femoral scan sites and not in spinal scan sites. In contrast, LSM showed clear positive correlations with BMD in some femoral and all spinal scan sites, as well as with BMC in certain femoral and spinal scan sites. However, LSM did not correlate with the bone area in any femoral or spinal scan sites. Besides, LSM showed a nonlinear association with these indicators. Subgroup analysis revealed a positive correlation between CAP and BMD only in individuals with CAP > 248 dB/m, BMI ≥ 25 kg/m, and LSM < 11.7 kPa. Additionally, in females and individuals with LSM < 11.7 kPa, LSM was positively correlated with BMD, whereas in those with LSM ≥ 11.7 kPa, LSM showed a negative correlation with BMD. Our findings highlighted a positive association between SLD and BMD; however, the association was likely influenced by liver fibrosis. Studies in large scale cohorts with a longer follow-up are warranted to elucidate the impacts of hepatic steatosis and associated pathologies on bone health.

摘要

最近,有人提议用代谢功能障碍相关脂肪性肝病(MASLD)取代先前称为非酒精性脂肪性肝病(NAFLD)的肝脏疾病,从而重新定义脂肪性肝病(SLD)的亚类。然而,SLD亚类的临床相关性及其与骨量的关系尚不清楚。在本研究中,我们旨在探讨常见的脂肪性肝病亚类与骨量之间的潜在关联。我们进行了一项横断面研究,使用了2017 - 2020年国家健康与营养检查调查(NHANES)的数据,纳入了4237名18岁及以上的参与者,这些参与者接受了振动控制瞬时弹性成像(VCTE)和双能X线吸收法(DXA)检查。采用加权广义线性模型分析SLD亚类与骨量变化(包括股骨和脊柱的骨矿物质含量(BMC)、骨面积和骨矿物质密度(BMD))之间的关联,并对潜在的协变量进行了调整。此外,采用加权广义相加模型评估受控衰减参数(CAP)、肝脏硬度测量值(LSM)与BMD之间的剂量反应关系。分别有2635名和1602名参与者纳入股骨和腰椎分析。与健康个体相比,所有三个SLD亚组(MASLD、MetALD和ALD)与股骨和脊柱的BMC及BMD之间均呈正相关,但未发现与骨面积有关联。此外,在所有股骨和脊柱扫描部位,CAP与BMD均呈强正相关。在一些股骨扫描部位和所有脊柱扫描部位,CAP与BMC也呈正相关,但仅在某些股骨扫描部位与骨面积有关联,而在脊柱扫描部位则无关联。相比之下,在一些股骨和所有脊柱扫描部位,LSM与BMD呈明显正相关,在某些股骨和脊柱扫描部位与BMC也呈正相关。然而,在任何股骨或脊柱扫描部位,LSM与骨面积均无相关性。此外,LSM与这些指标呈非线性关联。亚组分析显示,仅在CAP>248 dB/m、BMI≥25 kg/m²且LSM<11.7 kPa的个体中,CAP与BMD呈正相关。此外,在女性和LSM<11.7 kPa的个体中,LSM与BMD呈正相关,而在LSM≥11.7 kPa的个体中,LSM与BMD呈负相关。我们的研究结果突出了SLD与BMD之间的正相关;然而,这种关联可能受肝纤维化影响。有必要开展大规模队列的长期随访研究,以阐明肝脂肪变性及相关病变对骨骼健康的影响。

相似文献

1
Increased BMD in SLD Patients Without Advanced Hepatic Fibrosis: Evidence From the NHANES 2017-2020 Database.无晚期肝纤维化的非酒精性脂肪性肝病患者骨密度增加:来自2017 - 2020年美国国家健康与营养检查调查数据库的证据
Can J Gastroenterol Hepatol. 2025 Aug 11;2025:6969761. doi: 10.1155/cjgh/6969761. eCollection 2025.
2
Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate-to-severe psoriasis.累积甲氨蝶呤剂量与有中重度银屑病病史患者的肝纤维化无关。
Br J Dermatol. 2024 Jul 16;191(2):275-283. doi: 10.1093/bjd/ljae069.
3
Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community.社区中具有代谢和酒精风险个体的脂肪性肝病患病率、严重程度及决定因素
J Hepatol. 2025 Jul 4. doi: 10.1016/j.jhep.2025.06.020.
4
Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease.代谢功能障碍相关脂肪性肝病相关肝纤维化增加胰岛素抵抗、2 型糖尿病和慢性肾脏病的风险。
Eur J Gastroenterol Hepatol. 2024 Jun 1;36(6):802-810. doi: 10.1097/MEG.0000000000002767. Epub 2024 Mar 22.
5
Nonalcoholic Fatty Liver非酒精性脂肪肝
6
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
7
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.代谢相关脂肪性肝病和非酒精性脂肪性肝病的临床特征和病死率相似。
J Hepatol. 2024 May;80(5):694-701. doi: 10.1016/j.jhep.2024.01.014. Epub 2024 Jan 27.
8
Assessment of transient elastography in diagnosing MAFLD and the early effects of sleeve gastrectomy on MAFLD among the Chinese population.评估瞬时弹性成像技术在诊断 MAFLD 中的应用,以及袖状胃切除术对中国人 MAFLD 的早期影响。
Int J Surg. 2024 Apr 1;110(4):2044-2054. doi: 10.1097/JS9.0000000000001078.
9
Impact of alcohol consumption and muscle mass on bone mineral density in metabolic dysfunction and alcohol-associated liver disease (MetALD) and metabolic dysfunction-associated steatotic liver disease (MASLD).饮酒量和肌肉量对代谢功能障碍与酒精相关肝病(MetALD)及代谢功能障碍相关脂肪性肝病(MASLD)患者骨密度的影响。
Clin Nutr ESPEN. 2025 Jul 7;69:145-153. doi: 10.1016/j.clnesp.2025.07.002.
10
Associations of Cannabis Use, Metabolic Dysfunction-Associated Steatotic Liver Disease, and Liver Fibrosis in U.S. Adults.美国成年人中大麻使用、代谢功能障碍相关脂肪性肝病和肝纤维化之间的关联。
Cannabis Cannabinoid Res. 2024 Sep 17. doi: 10.1089/can.2024.0027.

本文引用的文献

1
The role of lipid metabolism in osteoporosis: Clinical implication and cellular mechanism.脂质代谢在骨质疏松症中的作用:临床意义与细胞机制
Genes Dis. 2023 Sep 20;11(4):101122. doi: 10.1016/j.gendis.2023.101122. eCollection 2024 Jul.
2
Current status and future trends of the global burden of MASLD.全球 MASLD 负担的现状和未来趋势。
Trends Endocrinol Metab. 2024 Aug;35(8):697-707. doi: 10.1016/j.tem.2024.02.007. Epub 2024 Feb 29.
3
Insights and implications of sexual dimorphism in osteoporosis.骨质疏松症中性别二态性的见解与意义。
Bone Res. 2024 Feb 18;12(1):8. doi: 10.1038/s41413-023-00306-4.
4
Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients.代谢相关脂肪性肝病和肝纤维化与 T2DM 患者骨密度及低骨量/骨质疏松症风险的相关性研究。
Front Endocrinol (Lausanne). 2023 Dec 4;14:1278505. doi: 10.3389/fendo.2023.1278505. eCollection 2023.
5
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease.肝硬化的代偿:揭开非酒精性脂肪性肝病的自然史演变。
Nat Rev Gastroenterol Hepatol. 2024 Jan;21(1):46-56. doi: 10.1038/s41575-023-00846-4. Epub 2023 Oct 5.
6
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk.代谢相关脂肪性肝病(MAFLD)发病机制的新见解:肠-肝-心轴的相互作用
Nutrients. 2023 Sep 14;15(18):3970. doi: 10.3390/nu15183970.
7
Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.对于非酒精性脂肪性肝病(NAFLD)的瘦患者,代谢功能障碍相关脂肪性肝病(MASLD)的定义优于代谢功能障碍相关脂肪性肝病(MAFLD)标准。
J Hepatol. 2024 Feb;80(2):e61-e62. doi: 10.1016/j.jhep.2023.07.031. Epub 2023 Aug 7.
8
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识:新的非酒精性脂肪性肝病命名。
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
9
Nonalcoholic Fatty Liver Disease Is Associated With Decreased Bone Mineral Density in Adults: A Systematic Review and Meta-Analysis.非酒精性脂肪性肝病与成年人骨密度降低相关:系统评价和荟萃分析。
J Bone Miner Res. 2023 Aug;38(8):1092-1103. doi: 10.1002/jbmr.4862. Epub 2023 Jun 12.
10
Changing epidemiology, global trends and implications for outcomes of NAFLD.非酒精性脂肪性肝病的流行病学变化、全球趋势及其对结局的影响。
J Hepatol. 2023 Sep;79(3):842-852. doi: 10.1016/j.jhep.2023.04.036. Epub 2023 May 9.